Core Laboratories (CLB) Tops Q3 EPS by 3c

Core Laboratories (NYSE: CLB) reported Q3 EPS of $0.18, $0.03 better than the analyst estimate of $0.15. Revenue for the quarter came in at $126 million versus the consensus estimate of $125.97 million.

GUIDANCE:

Core Laboratories sees Q4 2022 EPS of $0.17-$0.21, versus the consensus of $0.17. Core Laboratories sees Q4 2022 revenue of $126-131 million, versus the consensus of $129.98 million.

For earnings history and earnings-related data on Core Laboratories (CLB) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth